secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2023-01-31T23:59:59+00:00
Accession:  0001104659-23-008450
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec receives FDA Orphan Drug Exclusivity for PEDMARK; 7-year market exclusivity until 2029
--------------------------------------------------------------------------------

- FDA granted Orphan Drug Exclusivity to PEDMARK, providing 7-year market exclusivity from Sept. 20, 2022 to Sept. 20, 2029.
- PEDMARK is the first and only FDA-approved therapy to reduce cisplatin-induced ototoxicity in pediatric solid tumor patients.
- Company holds three Orange Book patents for PEDMARK, with protection until 2038-2039.
- FDA explicitly directed that PEDMARK is not substitutable with other sodium thiosulfate products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465923008450/0001104659-23-008450-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465923008450/tm235024d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-008450

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer